EUVIMEDEUVIMED entdecken
Crossref

Design and Synthesis of 2‐Aminopyrazolpyrimidopyridone Derivatives as RET V 804 M and RET G 810 C Kinase Inhibitors

Jiayi Shen iD, Anzhi Li, Jieman Lin, Jihu Liu, Shuyu Jia, Xu Zhao, Sheng Chen, Yongdong Li

Chemical Biology & Drug Design · 2025

DOI: 10.1111/cbdd.70191 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Chemical Biology & Drug Design, 2025. Verfasst von Jiayi Shen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, China. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Proto-Oncogene Proteins c-ret, Drug Design, Antineoplastic Agents. Die Arbeit nennt 38 Literaturangaben. Gefördert von: National Natural Science Foundation of China, The Jiangxi Provincial Natural Science Foundation, The Doctor Foundation of Gannan Normal University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncogenic conversion of the RET (rearranged during transfection) tyrosine kinase is associated with several cancers. The clinical therapeutic benefits of the second‐generation RET inhibitor pralsetinib are greatly compromised by acquired resistance mediated by solvent‐front mutations (e.g., RET G810R/S/C ). Herein, a class of 2‐aminopyrazolpyrimidopyridone derivatives as RET V804M and RET G810C solvent‐front mutant inhibitors were designed and synthesized for overcoming pralsetinib resistance. One of the optimal compounds, 7la , exhibited inhibitory potency against the proliferation of BaF3 cells harboring CCDC6‐RET V804M mutation with IC50 values of 0.271 μM. Interestingly, another one of these series compounds, 7qe , suppressed BaF3 cells harboring CCDC6‐RET V804M and CCDC6‐RET G810C mutations with IC 50 values of 0.841 and 0.272 μM, respectively. The compound also dose‐dependently suppressed the activation of RET and downstream signals. However, the relatively poor pharmacokinetic properties of these compounds will limit their further development. Therefore, compound 7qe might be a promising lead compound for the development of novel RET V804M and RET G810C inhibitors overcoming the clinical acquired resistance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsProto-Oncogene Proteins c-retDrug DesignAntineoplastic AgentsPyridonesPyrazolesHumansCell Line, TumorCell ProliferationMutationStructure-Activity RelationshipMolecular Docking SimulationAnimalsMice

Stichwörter der Autor:innen

2‐aminopyrazolpyrimidopyridonerearranged during transfection (RET) kinaseresistancesolvent‐front mutation

Substanzen

Protein Kinase InhibitorsProto-Oncogene Proteins c-retAntineoplastic AgentsPyridonesPyrazoles

Autor:innen und Institutionen

  • Jiangxi Provincial Key Laboratory of Synthetic Pharmaceutical Chemistry, Gannan Normal University, Ganzhou, China.
  • Jiangxi Chiralsyn Biological Medicine Co., LTD, Ganzhou, China.

ORCID-Profile: Jiayi Shen

Förderung

  • National Natural Science Foundation of China
  • The Jiangxi Provincial Natural Science Foundation
  • The Doctor Foundation of Gannan Normal University
  • Natural Science Foundation of Jiangxi Province

Zitieren

APA

Shen, J., Li, A., Lin, J., Liu, J., Jia, S., Zhao, X., Chen, S., & Li, Y. (2025). Design and Synthesis of 2‐Aminopyrazolpyrimidopyridone Derivatives as RET V 804 M and RET G 810 C Kinase Inhibitors. Chemical Biology & Drug Design. https://doi.org/10.1111/cbdd.70191

Vancouver

Shen J, Li A, Lin J, Liu J, Jia S, Zhao X, et al. Design and Synthesis of 2‐Aminopyrazolpyrimidopyridone Derivatives as RET V 804 M and RET G 810 C Kinase Inhibitors. Chemical Biology & Drug Design. 2025. doi:10.1111/cbdd.70191

BibTeX
@article{Shen2025,
  author = {Shen, Jiayi and Li, Anzhi and Lin, Jieman and Liu, Jihu and Jia, Shuyu and Zhao, Xu and Chen, Sheng and Li, Yongdong},
  title = {Design and Synthesis of 2‐Aminopyrazolpyrimidopyridone Derivatives as RET V 804 M and RET G 810 C Kinase Inhibitors},
  journal = {Chemical Biology & Drug Design},
  year = {2025},
  doi = {10.1111/cbdd.70191}
}
Kostenlos starten →